![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, November 16, 2020 9:06:30 AM
Then first would come the 1st line treatments. Where there are two primary ones. Would request an add on treatment that quadruples the chance of successful surgical removal of the primary tumor. If surgery is successful then one has 2+ yrs. And in that time one could try an immunotherapy to prolong remission. Also, attempt the "personalized" medicine approach. Test for such things as BRCA1/BRCA2 mutations which could allow the use of PARP inhibitors- as part of maintenance therapy(?).
Then would come 2nd line therapy. Nanoliposomal irinotecan either alone or in combo with other drugs is gaining for 2nd line usage. Recently approved in the OFF (Oxaliplatin/Folinic Acid/5-FU) protocol.
Likewise in 2nd line "personalized" medicine comes into play. NTRK fusions, if present can be treated with larotrectinib or entrectinib.
If now a 2nd line patient, and wanting to go to the bleeding edge, one could try getting into a CT involving immunotherapy with an IL-15 agonist, and an anti-PD-L1 drug in combo with chemo.
So where does the desperation of "and had no other treatment solutions available" come from? And we're not through...
One's oncologist could explore what it would take to get one into a BL-8040 CT. And if that isn't available, and one is becoming more fragile or unable to tolerate chemo, there is GRASPA. Extremely low toxicity. None of the usual chemo effects.
What one wouldn't do is read a Kenny PR pump, and then "be cursing the fda for not letting this technology move forward". Because there's no sound science that says the Kenny Wonder Treatment will do anything. Instead if one was seeking as a last ditch effort some palliative relief using an alkylating drug, then one would inquire about Glufosfamide. If approved by then for 2nd line cancer, then inquire from the oncologist whether to go off label, combining it with immunotherapies. Where any subsequent cursing involves insurance companies for not wanting to cover the treatment.
In summary... the Kenny PR pumps can imply there is an "un-met" need, and that there are no 2nd line treatments available, all that he wants to. But it isn't reality. There's a myriad of treatments, with more on the way. Treatments far superior to the 20 yr old antiquated Kenny Wonder Treatment.
The Jewel of the Mind is Colored with the Hue of what it Imagines
Recent PMCB News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/21/2023 09:04:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/18/2023 10:04:06 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 09/15/2023 09:00:03 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/12/2023 01:56:25 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM